Interpreting EGFR-TKI Evidence for Early-Stage EGFR-Mutated NSCLC

In this segment, Dr. Alexander Spira and Dr. Ticiana Leal discuss how clinicians interpret EGFR tyrosine kinase inhibitor (TKI) data across different clinical trials and apply these findings to early-stage EGFR-mutated non–small cell lung cancer (NSCLC). Dr. Leal highlights the importance of evaluating key trial characteristics, including patient populations, disease stage, endpoints, and study design, when assessing the relevance of data to real-world practice. The discussion emphasizes the need to consider differences in geographic populations, mutation subtypes, and prior treatments, which may influence outcomes and generalizability. Dr. Leal also notes that clinicians often rely on a combination of clinical trial evidence, guideline recommendations, and real-world experience to inform decision-making. This segment underscores the importance of critical appraisal of the evidence to ensure that treatment strategies are appropriately tailored to patients with early-stage EGFR-mutated NSCLC.